Premium
COMBINATION OF RITUXIMAB‐LENALIDOMIDE‐IBRUTINIB IN RELAPSED/REFRACTORY PRIMARY CNS LYMPHOMA: A COHORT STUDY OF THE LOC NETWORK
Author(s) -
Houillier C,
MoluçonChabrot C.,
Moles M.P.,
Willems L.,
Ahle G.,
Waultier A.,
Fornecker L.M.,
HoangXuan K.,
Soussain C.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.73_2880
Subject(s) - lenalidomide , medicine , rituximab , ibrutinib , refractory (planetary science) , thalidomide , oncology , cohort , neutropenia , lymphoma , gastroenterology , chemotherapy , surgery , multiple myeloma , leukemia , chronic lymphocytic leukemia , physics , astrobiology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom